Understanding resistance to EGFR inhibitors—impact on future treatment strategies

被引：0
作者：
Deric L. Wheeler
Emily F. Dunn
Paul M. Harari
机构：
[1] University of Wisconsin Comprehensive Cancer Center,Department of Human Oncology
[2] University of Wisconsin Comprehensive Cancer Center,Department of Human Oncology
来源：
Nature Reviews Clinical Oncology | 2010年 / 7卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
EGFR is one of the most studied targets in oncology, and several inhibitors have shown promising results in selected patient populations. However, intrinsic and acquired resistance to these targeted therapies is increasingly recognized. The authors of this Review describe the successful translation of EGFR inhibitors to the clinic, and highlight the mechanisms of resistance to these agents that limit their long-term efficacy. Understanding these processes will allow researchers to develop therapies that overcome resistance and ultimately lead to more successful outcomes.
引用
收藏
页码：493 / 507
页数：14
相关论文
共 275 条
[31]  
Kawamoto T(2010)Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas J. Clin. Oncol. 28 357-360
[32]  
Honegger AM(2005)Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer Nat. Rev. Cancer 5 341-354
[33]  
Honegger AM(1999)Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Proc. Natl Acad. Sci. USA 96 4995-5000
[34]  
Redemann N(2009)ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 9 463-475
[35]  
Fry DW(1994)The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proc. Natl Acad. Sci. USA 91 8132-8136
[36]  
Osherov N(1995)Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 EMBO J. 14 4267-4275
[37]  
Levitzki A(2008)Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity Cancer Cell 13 385-393
[38]  
Wakeling AE(1991)Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3 Hepatology 13 15-20
[39]  
Bonner JA(1995)Survival of cancer cells is maintained by EGFR independent of its kinase activity Endocrinology 136 3163-3172
[40]  
Herbst RS(2001)Localization of epidermal growth factor receptor in hepatocyte nuclei Nat. Cell Biol. 3 802-808
12345678910